Startseite Technik AI-driven drug design exploring molecular docking and lead optimization using machine learning algorithms
Kapitel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

AI-driven drug design exploring molecular docking and lead optimization using machine learning algorithms

  • A. Muniyappan , D.M. Kalai Selvi , S. Ramkumar , K. Suresh Kumar und Ezhil E. Nithila
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

AI that has not been integrated with preclinical testing experimental methods is another effective means through which medicationmedication development can be hastened. This book chapter examines the several uses of AI in preclinical testing, namely as target and validation identifications, hit identification, molecular docking, lead optimization, toxicity assessment, and biomarker identification. For the purpose of uncovering the disease mechanisms and novel therapeutic measures, the omics information, capabilities of predicting the drug activities and properties, enhancing screening assays, and fusing multiple dimensions of data are all tackled by machine learning. AI tools help scientists identify more effective and safer drug candidates, enhance the implementation of precision medicine, enhance the accuracy, sensitivity, and variability of preclinical testing assays. This work can help understand how AI can change the process of creating drugsdrugs and provides a detailed evaluation of the current state of AI implementation during preclinical studies.

Abstract

AI that has not been integrated with preclinical testing experimental methods is another effective means through which medicationmedication development can be hastened. This book chapter examines the several uses of AI in preclinical testing, namely as target and validation identifications, hit identification, molecular docking, lead optimization, toxicity assessment, and biomarker identification. For the purpose of uncovering the disease mechanisms and novel therapeutic measures, the omics information, capabilities of predicting the drug activities and properties, enhancing screening assays, and fusing multiple dimensions of data are all tackled by machine learning. AI tools help scientists identify more effective and safer drug candidates, enhance the implementation of precision medicine, enhance the accuracy, sensitivity, and variability of preclinical testing assays. This work can help understand how AI can change the process of creating drugsdrugs and provides a detailed evaluation of the current state of AI implementation during preclinical studies.

Heruntergeladen am 7.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/9783111503202-007/html
Button zum nach oben scrollen